JPMorgan Chase & Co. upgraded shares of Janus Henderson Group (NYSE:JHG – Free Report) from a neutral rating to an overweight rating in a research note released on Wednesday, MarketBeat reports.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat.com reports. Two research ...

Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs ...

Janus Henderson Group (JHG) is undergoing a turnaround, with improved revenue and earnings. Analysts have upgraded their rating and price target for the company.

Fintel reports that on February 5, 2025, JP Morgan upgraded their outlook for Janus Henderson Group (NYSE:JHG) from Neutral ...

JPMorgan upgraded Janus Henderson (JHG) to Overweight from Neutral with a price target of $53, up from $44. The firm sees Janus as the ...

Ali Dibabj, Janus Henderson CEO, joins 'Money Movers' to discuss how investors should navigate today's tariff environment, the bond market's reaction, and much more.

Learn more about whether Janus Henderson Group plc or StepStone Group Inc. is a better investment based on AAII's A+ Investor ...

Pro, an updated version of its multimodal model, Janus. The new model improves training strategies, data scaling, and model ...